CD266 antibody | ITEM-4
Filter by Application:F Reset
|Mouse anti Human CD266 antibody, clone ITEM-4 recognizes human tumor necrosis factor receptor superfamily member 12A, also known as CD266, Fibroblast growth factor-inducible immediate-early response protein 14 or Tweak-receptor. CD266 is a 102 amino acid ~14 kDa type I transmembrane glycoprotein and member of the tumour necrosis factor receptor superfamily (TNFRSF12A) expressed by a variety of tissues, including the heart, lung and kidney, and at elevated levels by human brain and liver tumors.
The interaction between CD266 and its ligand CD255 (TWEAK), induces the proliferation and migration of endothelial cells and also angiogenesis, and CD255-induced apoptosis of some tumor cell lines is mediated by CD266 (Nakayama et al. 2003).
Mouse anti Human CD266 antibody, clone ITEM-4 is cross-reactive with mouse CD266, and also with Rat-1 fibroblastoid cells in flow cytometry.
- Target Species
- Species Cross-Reactivity
Target Species Cross Reactivity Mouse Rat
- N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Carrier Free
- Human CD266 transfected P815 cells.
- Approx. Protein Concentrations
- IgG concentration 1.0mg/ml
- Fusion Partners
- Spleen cells from immunized BALB/c mice were fused with cells of the P3U1 mouse myeloma cell line.
- For research purposes only
- 12 months from date of despatch
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Frozen|
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.
References for CD266 antibody
Nakayama, M. et al. (2003) Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death.
J Immunol. 170 (1): 341-8.
Nakayama, M. et al. (2003) Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies.
Biochem Biophys Res Commun. 306 (4): 819-25.
Winkles, J.A. and Brown,S. (2010) Targeted Therapy of Fn14-Positive Breast Tumors Using a TWEAK-CytotoxinFusion Protein or Noncovalent Complex.
U.S. Army Medical Research and Materiel Command, Annual Report
Girgenrath, M. et al. (2006) TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration.
EMBO J. 25: 5826-39.
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.Yes, sign me up